224 related articles for article (PubMed ID: 30312362)
41. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
[TBL] [Abstract][Full Text] [Related]
42. Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.
Faleck DM; Salmasian H; Furuya EY; Larson EL; Abrams JA; Freedberg DE
Am J Gastroenterol; 2016 Nov; 111(11):1641-1648. PubMed ID: 27575714
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
[TBL] [Abstract][Full Text] [Related]
44. Mortality impact of empirical antimicrobial therapy in ESBL- and AmpC-producing Enterobacteriaceae bacteremia in an Australian tertiary hospital.
Lim CL; Spelman D
Infect Dis Health; 2019 Aug; 24(3):124-133. PubMed ID: 30928569
[TBL] [Abstract][Full Text] [Related]
45. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study.
Harris PNA; Pezzani MD; Gutiérrez-Gutiérrez B; Viale P; Hsueh PR; Ruiz-Garbajosa P; Venditti M; Tumbarello M; Navarro-Francisco C; Calbo E; Akova M; Giamarellou H; Oliver A; Almirante B; Gasch O; Martínez-Martínez L; Schwaber MJ; Daikos G; Pitout J; Peña C; Hernández-Torres A; Doi Y; Pérez F; Tuon FF; Tacconelli E; Carmeli Y; Bonomo RA; Pascual Á; Paterson DL; Rodríguez-Baño J;
Int J Antimicrob Agents; 2017 Nov; 50(5):664-672. PubMed ID: 28782704
[TBL] [Abstract][Full Text] [Related]
46. Impact of real-time notification of Clostridium difficile test results and early initiation of effective antimicrobial therapy.
Polen CB; Judd WR; Ratliff PD; King GS
Am J Infect Control; 2018 May; 46(5):538-541. PubMed ID: 29305281
[TBL] [Abstract][Full Text] [Related]
47. Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection.
Webb BJ; Subramanian A; Lopansri B; Goodman B; Jones PB; Ferraro J; Stenehjem E; Brown SM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964789
[No Abstract] [Full Text] [Related]
48. Evaluation of early clinical failure criteria for gram-negative bloodstream infections.
Rac H; Gould AP; Bookstaver PB; Justo JA; Kohn J; Al-Hasan MN
Clin Microbiol Infect; 2020 Jan; 26(1):73-77. PubMed ID: 31158519
[TBL] [Abstract][Full Text] [Related]
49. Stratification of the impact of inappropriate empirical antimicrobial therapy for Gram-negative bloodstream infections by predicted prognosis.
Cain SE; Kohn J; Bookstaver PB; Albrecht H; Al-Hasan MN
Antimicrob Agents Chemother; 2015 Jan; 59(1):245-50. PubMed ID: 25348527
[TBL] [Abstract][Full Text] [Related]
50. Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent Clostridiodes difficile infection relapses.
Caroff DA; Menchaca JT; Zhang Z; Rhee C; Calderwood MS; Kubiak DW; Yokoe DS; Klompas M
Infect Control Hosp Epidemiol; 2019 Jun; 40(6):662-667. PubMed ID: 31030679
[TBL] [Abstract][Full Text] [Related]
51. Derivation of a quick Pitt bacteremia score to predict mortality in patients with Gram-negative bloodstream infection.
Battle SE; Augustine MR; Watson CM; Bookstaver PB; Kohn J; Owens WB; Baddour LM; Al-Hasan MN
Infection; 2019 Aug; 47(4):571-578. PubMed ID: 30737765
[TBL] [Abstract][Full Text] [Related]
52. Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship.
Harpe SE; Inocencio TJ; Pakyz AL; Oinonen MJ; Polk RE
Pharmacotherapy; 2012 Aug; 32(8):744-54. PubMed ID: 23307522
[TBL] [Abstract][Full Text] [Related]
53. Evaluating the Effectiveness of an Antimicrobial Stewardship Program on Reducing the Incidence Rate of Healthcare-Associated Clostridium difficile Infection: A Non-Randomized, Stepped Wedge, Single-Site, Observational Study.
DiDiodato G; McArthur L
PLoS One; 2016; 11(6):e0157671. PubMed ID: 27309536
[TBL] [Abstract][Full Text] [Related]
54. Impact of antimicrobial strategies on clinical outcomes of adults with septic shock and community-onset Enterobacteriaceae bacteremia: de-escalation is beneficial.
Lee CC; Lee NY; Chen PL; Hong MY; Chan TY; Chi CH; Ko WC
Diagn Microbiol Infect Dis; 2015 Jun; 82(2):158-64. PubMed ID: 25796557
[TBL] [Abstract][Full Text] [Related]
55. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
[TBL] [Abstract][Full Text] [Related]
56. Examining the clinical impact of rapid multiplex polymerase chain reaction-based diagnostic testing for bloodstream infections in a national cohort of the Veterans Health Administration.
Britt NS; Khader K; He T; Willson TM; Effiong A; Timbrook TT; Potter EM; Lodise TP
Pharmacotherapy; 2023 Jan; 43(1):24-34. PubMed ID: 36484553
[TBL] [Abstract][Full Text] [Related]
57. Evaluating antimicrobial duration for Gram-negative bacteremia in patients with neutropenia due to hematologic malignancy or hematopoietic stem cell transplantation.
Ranganath N; Yetmar ZA; McCandless AR; Rivera CG; Lahr BD; Tande AJ; Shah AS
Transpl Infect Dis; 2023 Oct; 25(5):e14085. PubMed ID: 37279240
[TBL] [Abstract][Full Text] [Related]
58. Clinical impact of matrix-assisted laser desorption ionization-time of flight mass spectrometry combined with antimicrobial stewardship interventions in patients with bloodstream infections in a Japanese tertiary hospital.
Niwa T; Yonetamari J; Hayama N; Fujibayashi A; Ito-Takeichi S; Suzuki K; Ohta H; Niwa A; Tsuchiya M; Yamamoto M; Hatakeyama D; Hayashi H; Obara M; Sugiyama T; Baba H; Suzuki A; Murakami N
Int J Clin Pract; 2019 May; 73(5):e13332. PubMed ID: 30810264
[TBL] [Abstract][Full Text] [Related]
59. Modeling inpatient and outpatient antibiotic stewardship interventions to reduce the burden of Clostridioides difficile infection in a regional healthcare network.
Rhea S; Jones K; Endres-Dighe S; Munoz B; Weber DJ; Hilscher R; MacFarquhar J; Sickbert-Bennett E; DiBiase L; Marx A; Rineer J; Lewis J; Bobashev G;
PLoS One; 2020; 15(6):e0234031. PubMed ID: 32525887
[TBL] [Abstract][Full Text] [Related]
60. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.
Gutiérrez-Gutiérrez B; Bonomo RA; Carmeli Y; Paterson DL; Almirante B; Martínez-Martínez L; Oliver A; Calbo E; Peña C; Akova M; Pitout J; Origüen J; Pintado V; García-Vázquez E; Gasch O; Hamprecht A; Prim N; Tumbarello M; Bou G; Viale P; Tacconelli E; Almela M; Pérez F; Giamarellou H; Cisneros JM; Schwaber MJ; Venditti M; Lowman W; Bermejo J; Hsueh PR; Mora-Rillo M; Gracia-Ahulfinger I; Pascual A; Rodríguez-Baño J;
J Antimicrob Chemother; 2016 Jun; 71(6):1672-80. PubMed ID: 26907184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
